Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the ...

Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm ...

Novo Holdings reported a 2024 income of 60B Danish kroner, with its investment portfolio delivering an 18% return, up from 9.4% in 2023. Novo Holdings added 43 new companies to its portfolio in ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Meanwhile, Novo Nordisk has intensified legal and regulatory actions to curb unauthorized compounded semaglutide, ahead of expected U.S. regulatory decisions in late May.

LONDON/COPENHAGEN, April 2 (Reuters) - Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk (NOVOb.CO), opens new tab, nearly doubled annual income and investment returns ...